JP2005512528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512528A5 JP2005512528A5 JP2003551507A JP2003551507A JP2005512528A5 JP 2005512528 A5 JP2005512528 A5 JP 2005512528A5 JP 2003551507 A JP2003551507 A JP 2003551507A JP 2003551507 A JP2003551507 A JP 2003551507A JP 2005512528 A5 JP2005512528 A5 JP 2005512528A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- nucleic acid
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 230000002792 vascular Effects 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000036490 Arterial inflammations Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010073734 Microembolism Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 208000023589 ischemic disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 210000005167 vascular cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33999501P | 2001-12-10 | 2001-12-10 | |
| PCT/US2002/039353 WO2003050504A2 (en) | 2001-12-10 | 2002-12-10 | Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512528A JP2005512528A (ja) | 2005-05-12 |
| JP2005512528A5 true JP2005512528A5 (enExample) | 2006-02-02 |
Family
ID=23331451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003551507A Pending JP2005512528A (ja) | 2001-12-10 | 2002-12-10 | １４１９、５８７６５および２２１０を用いて心血管疾患を処置するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20030152574A1 (enExample) |
| EP (1) | EP1451369A4 (enExample) |
| JP (1) | JP2005512528A (enExample) |
| AU (1) | AU2002360531A1 (enExample) |
| WO (1) | WO2003050504A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI111745B (fi) * | 2001-12-19 | 2003-09-15 | Kemira Chemicals Oy | Parannettu kartonginvalmistusmenetelmä |
| WO2003053363A2 (en) * | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| US20050037946A1 (en) * | 2003-01-13 | 2005-02-17 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419 |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| WO2008019351A2 (en) | 2006-08-04 | 2008-02-14 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to diacylglycerol acyltransferase 1 |
| US10745754B2 (en) | 2013-11-27 | 2020-08-18 | Bioscreening & Diagnostics Llc | Method for predicting congenital heart defect |
| PE20180800A1 (es) | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US161831A (en) * | 1875-04-06 | Improvement in processes of purifying galvanizers dross | ||
| US170691A (en) * | 1875-12-07 | Improvement in spring-equalizers | ||
| US5843749A (en) * | 1991-07-26 | 1998-12-01 | Regeneron Pharmaceuticals, Inc. | Ehk and Ror tyrosine kinases |
| US5747033A (en) * | 1993-10-28 | 1998-05-05 | Regeneron Pharmaceuticals, Inc. | Method of enhancing the biological activity of Eph family ligands |
| CA2189028A1 (en) * | 1994-04-15 | 1995-10-26 | Gary M. Fox | Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases |
| AU716924B2 (en) * | 1994-10-27 | 2000-03-09 | Genentech Inc. | AL-1 neurotrophic factor, a ligand for an EPH related tyrosine kinase receptor |
| US20030161831A1 (en) * | 2001-02-23 | 2003-08-28 | Sylvaine Cases | Mono-and diacylglycerol acyltransferases and methods of use thereof |
| WO2003053363A2 (en) * | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| EP1470240A4 (en) * | 2002-02-01 | 2006-08-30 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2 |
-
2002
- 2002-12-10 EP EP02795793A patent/EP1451369A4/en not_active Ceased
- 2002-12-10 WO PCT/US2002/039353 patent/WO2003050504A2/en not_active Ceased
- 2002-12-10 AU AU2002360531A patent/AU2002360531A1/en not_active Abandoned
- 2002-12-10 JP JP2003551507A patent/JP2005512528A/ja active Pending
- 2002-12-10 US US10/316,124 patent/US20030152574A1/en not_active Abandoned
-
2005
- 2005-02-24 US US11/064,551 patent/US20050142604A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522999A5 (enExample) | ||
| JP2005516605A5 (enExample) | ||
| KR20220044486A (ko) | 샘플 내 분석 물질의 신호 인코딩 방법 | |
| CN102099470B (zh) | 用于诊断动脉硬化的多肽标记、用该标记等检测动脉硬化的方法以及用于诊断动脉硬化的试剂盒 | |
| JP2023529682A (ja) | 試料中の異なる分析物を検出するための多重的方法 | |
| JP2010508855A5 (enExample) | ||
| JP2003520050A (ja) | タンパク質分析のための高感度多重化診断アッセイ法 | |
| JP2007506426A5 (enExample) | ||
| JP2005512528A5 (enExample) | ||
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| US6255060B1 (en) | Method of detecting protein by immuno RNA | |
| JP2004526421A5 (enExample) | ||
| JP2005535289A5 (enExample) | ||
| JP2006503575A5 (enExample) | ||
| KR20190012715A (ko) | Park7, apex1 및 s1pr1 단백질을 포함하는 혈관질환 진단용 바이오마커 | |
| JP2005525112A5 (enExample) | ||
| Garcáa–Vitoria et al. | Expression of neuronal nitric oxide synthase in several cell types of the rat gastric epithelium | |
| JP2005516604A5 (enExample) | ||
| JP2005508169A5 (enExample) | ||
| KR101351647B1 (ko) | 인간 심근 트로포닌 ⅰ에 특이적으로 결합하는 ｄｎａ 압타머 | |
| JP2005508633A5 (enExample) | ||
| Yang et al. | Biochemical characterization of the developmental stage-and tissue-specific erythroid transcription factor, NF-E4 | |
| JP2005509174A5 (enExample) | ||
| JP2005507673A5 (enExample) | ||
| JP2005514013A5 (enExample) |